US 11,691,972 B2
Compounds for targeted degradation of BRD9
Christopher G. Nasveschuk, Stoneham, MA (US); Rhamy Zeid, Arlington, MA (US); Ning Yin, Lexington, MA (US); Katrina L. Jackson, Weston, MA (US); Gesine Kerstin Veits, Sommerville, MA (US); Moses Moustakim, Brighton, MA (US); and Jeremy L. Yap, Sudbury, MA (US)
Assigned to C4 Therapeutics, Inc., Watertown, MA (US)
Filed by C4 Therapeutics, Inc., Watertown, MA (US)
Filed on Dec. 2, 2021, as Appl. No. 17/541,035.
Application 17/541,035 is a continuation of application No. PCT/US2021/021240, filed on Mar. 5, 2021.
Claims priority of provisional application 63/061,659, filed on Aug. 5, 2020.
Claims priority of provisional application 62/985,774, filed on Mar. 5, 2020.
Prior Publication US 2022/0098194 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); C07D 401/14 (2006.01); A61P 35/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01); C07D 401/14 (2013.01)] 10 Claims
 
1. A compound of Formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein:
Q1 is independently at each occurrence selected from the group consisting of NH, N(alkyl), N(haloalkyl), CH2, O, and S;
X3 is N, CH, or CR3;
X10 is C(R7)2, C(O), or O;
X11 is heterocycle optionally substituted with 1, 2, or 3 groups independently selected from R3;
X16 is selected from the group consisting of N, CH, and CR4;
R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, alkoxy, C1-C4alkyl, C1-C4haloalkyl, cycloalkyl, fluorine, chlorine, bromine, and iodine;
each R4 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, C1-C4alkoxy, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C4alkyl, fluorine, chlorine, bromine, and iodine;
each R7 is independently hydrogen, methyl, or ethyl; and
R8 is hydrogen, C1-C4alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl.